US 12,486,300 B2
Mithramycin oxime derivatives having increased selectivity and anti-cancer activity
Jon S. Thorson, Lexington, KY (US); Jurgen Rohr, Lexington, KY (US); Markos Leggas, Lexington, KY (US); Joseph M. Eckenrode, Lexington, KY (US); Yinan Zhang, Jiangsu (CN); Yang Liu, Lexington, KY (US); Jianjun Zhang, Lexington, KY (US); and Khaled Attia Shaaban Mahmoud, Lexington, KY (US)
Assigned to University of Kentucky Research Foundation, Lexington, KY (US)
Filed by University of Kentucky Research Foundation, Lexington, KY (US)
Filed on Oct. 11, 2022, as Appl. No. 17/963,537.
Application 17/963,537 is a continuation in part of application No. 16/670,707, filed on Oct. 31, 2019, granted, now 11,466,045.
Claims priority of provisional application 62/753,205, filed on Oct. 31, 2018.
Prior Publication US 2023/0132854 A1, May 4, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 15/244 (2006.01); A61P 35/00 (2006.01); C07H 15/26 (2006.01)
CPC C07H 15/244 (2013.01) [A61P 35/00 (2018.01); C07H 15/26 (2013.01)] 12 Claims
 
1. A compound having the following formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of substituted or unsubstituted amino acid, amino acid dipeptide, acyl-amino acid, and acyl-amino acid dipeptide.